

VER-49009

Catalog No: tcsc2845

 Available Sizes

 Size: 2mg

 Size: 5mg

 Size: 10mg

 Size: 50mg

 Size: 100mg

 Dize: 100mg

 Specifications

 CAS No:

 558640-51-0

 Formula:

 C₁₉H₁₈ClN₃O₄

Pathway: Metabolic Enzyme/Protease;Cell Cycle/DNA Damage

Target: HSP;HSP

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Alternative Names:

CCT 129397

Copyright 2021 Taiclone Biotech Corp.



Observed Molecular Weight:

387.82

Product Description


VER-49009 is a **Hsp90** inhibitor, with an IC_{50} of 25 nM and a K_d of 78 nM.

IC50 & Target: IC50: 25 nM (Hsp90)^[1]

Kd: 78 nM (Hsp90)^[2]

In Vitro: VER-49009 is a Hsp90 inhibitor, with an IC₅₀ of 25 nM. VER-49009 binds to the ATPase of full length yeast Hsp90 protein, with an IC₅₀ of 140 nM^[1]. VER-49009 inhibits Hsp90, with a K_d of 78 nM. VER-49009 also shows antiproliferative activities against various human cancer cells, with a mean GI_{50} of 685 ± 119 nM. VER-49009 suppresses the proliferation of human umbilical vein endothelial cells (HUVEC) with GI_{50} values of 444 ± 91.1 nM, and shows higher GI_{50} s against nontumorigenic human breast (MCF10a) and prostate (PNT2) epithelial cells. VER-49009 displays no differences in cellular activities of isogenic cell lines, and these activities are independent of NQO1 expression^[2]. VER-49009 inhibits the proliferation (1, 2.5 µM), induces G2 phase arrest and reduces total Akt and phospho-Akt expression levels in CFSC cells (1-5 µM)^[3].

In Vivo: VER-49009 (4 mg/kg, i.p.) results in clear depletion of ERBB2 at 3 and 8 h following the final dose, with client protein levels returning to normal by 24 h, in the athymic mice bearing well-established OVCAR3 human ovarian ascites tumors^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.